FDA Approves Two Prostate Cancer Treatments: Lutetium Lu 177 Vipivotide Tetraxetan and Rucaparib

The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) in combination with an androgen receptor pathway inhibitor (ARPI) for adult patients with PSMA-positive metastatic hormone-sensitive prostate cancer. Additionally, the FDA granted full approval to rucaparib (Rubraca) for adults with metastatic castration-resistant prostate cancer (mCRPC) with a deleterious BRCA mutation who have received prior androgen receptor–directed therapy.